Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 37
Filter
1.
J Cardiothorac Vasc Anesth ; 35(1): 51-58, 2021 Jan.
Article in English | MEDLINE | ID: mdl-32868152

ABSTRACT

OBJECTIVE: The present study investigated outcomes in patients with vasoplegia after cardiac surgery treated with angiotensin II plus standard-of-care vasopressors. Vasoplegia is a common complication in cardiac surgery with cardiopulmonary bypass and is associated with significant morbidity and mortality. Approximately 250,000 cardiac surgeries with cardiopulmonary bypass are performed in the United States annually, with vasoplegia occurring in 20%to-27% of patients. DESIGN: Post-hoc analysis of the Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) study. SETTING: Multicenter, multinational study. PARTICIPANTS: Sixteen patients with vasoplegia after cardiac surgery with cardiopulmonary bypass were enrolled. INTERVENTIONS: Angiotensin II plus standard-of-care vasopressors (n = 9) compared with placebo plus standard-of-care vasopressors (n = 7). MEASUREMENTS AND MAIN RESULTS: The primary endpoint was mean arterial pressure response (mean arterial pressure ≥75 mmHg or an increase from baseline of ≥10 mmHg at hour 3 without an increase in the dose of standard-of-care vasopressors). Vasopressor sparing and safety also were assessed. Mean arterial pressure response was achieved in 8 (88.9%) patients in the angiotensin II group compared with 0 (0%) patients in the placebo group (p = 0.0021). At hour 12, the median standard-of-care vasopressor dose had decreased from baseline by 76.5% in the angiotensin II group compared with an increase of 7.8% in the placebo group (p = 0.0013). No venous or arterial thrombotic events were reported. CONCLUSION: Patients with vasoplegia after cardiac surgery with cardiopulmonary bypass rapidly responded to angiotensin II, permitting significant vasopressor sparing.


Subject(s)
Cardiac Surgical Procedures , Vasoplegia , Angiotensin II , Blood Pressure , Cardiac Surgical Procedures/adverse effects , Cardiopulmonary Bypass/adverse effects , Humans , Vasoconstrictor Agents/pharmacology , Vasoconstrictor Agents/therapeutic use , Vasoplegia/diagnosis , Vasoplegia/drug therapy , Vasoplegia/etiology
2.
J Cardiothorac Vasc Anesth ; 34(1): 267-277, 2020 Jan.
Article in English | MEDLINE | ID: mdl-30930139

ABSTRACT

The application and evolution of total endoscopic robotic cardiac surgery (TERCS) has become greater as institutions and surgeons become more comfortable with robotic technology. Over the years many improvements have been made to facilitate technically challenging cardiac procedures using robotics and increase overall survival and quality of life for these patients. However, a dedicated multidisciplinary approach led by a core group of clinicians is necessary for good patient experience and outcomes. In addition, good communication and performance improvement measures with attention to detailed perioperative management are essential to a successful robotic cardiac program.


Subject(s)
Anesthetics , Cardiac Surgical Procedures , Robotics , Humans , Minimally Invasive Surgical Procedures , Quality of Life
3.
J Cardiothorac Vasc Anesth ; 34(9): 2484-2491, 2020 Sep.
Article in English | MEDLINE | ID: mdl-31812565

ABSTRACT

Coronary artery bypass grafting represents one of the most commonly performed cardiac surgeries worldwide. Recently, interest has increased in providing patients with a less invasive approach to cardiac surgery, such as thoracotomy and endoscopic techniques using robotic technology as an alternative to traditional sternotomy. As the population gets older, the need for additional methods to provide care for sick patients will continue to expand. These advancements will further allow physicians to provide cardiac surgical procedures with less pain and faster recovery for patients.


Subject(s)
Anesthetics , Cardiac Surgical Procedures , Robotic Surgical Procedures , Robotics , Coronary Artery Bypass , Humans , Minimally Invasive Surgical Procedures , Treatment Outcome
4.
J Cardiothorac Vasc Anesth ; 34(1): 1-11, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31759862

ABSTRACT

This highlights in our specialty for 2019 begin with the ongoing major developments in transcatheter valve interventions. Thereafter, the advances in left ventricular assist devices are reviewed. The recent focus on conduit selection and robotic options in coronary artery bypass surgery are then explored. Finally, this special articles closes with a discussion of pulmonary hypertension in noncardiac surgery, anesthetic technique in cardiac surgery, as well as postoperative pneumonia and its outcome consequences.


Subject(s)
Anesthesia , Anesthesiology , Cardiac Surgical Procedures , Heart Valve Prosthesis Implantation , Cardiac Surgical Procedures/adverse effects , Coronary Artery Bypass , Humans , Treatment Outcome
5.
Semin Cardiothorac Vasc Anesth ; 23(3): 282-292, 2019 Sep.
Article in English | MEDLINE | ID: mdl-29871563

ABSTRACT

Since the 1960s when the first aortic surgical aortic valve replacement (SAVR) was performed, continuous growth in the field of valvular technology has occurred. Although SAVR remains a lifesaving procedure, minimally invasive transcatheter aortic valve replacement has revolutionized and expanded aortic valve replacement to patients who were not previously SAVR candidates, increasing their quality of life and survival. Since its introduction in the United States in 2011, the technology and practice have rapidly expanded. Hybrid techniques have been developed that combine surgical access to the vasculature with valvular deployment over transcatheter systems. This literature review aims to describe the differences between the current available valve technologies, review approaches to surgical technique, discuss anesthetic considerations, and look forward to future directions, trends, and challenges.


Subject(s)
Aortic Valve Stenosis/surgery , Quality of Life , Transcatheter Aortic Valve Replacement/methods , Anesthetics/administration & dosage , Humans , Survival , Transcatheter Aortic Valve Replacement/trends
7.
J Cardiothorac Vasc Anesth ; 33(2): 511-520, 2019 02.
Article in English | MEDLINE | ID: mdl-30502310

ABSTRACT

Patients undergoing cardiovascular surgery may be exposed to heparin before surgery, during cardiopulmonary bypass (CPB), or in the immediate postoperative period. For this reason, cardiovascular surgery patients are at increased risk for heparin-induced thrombocytopenia (HIT), occurring in 1 to 3% of patients. The diagnosis of HIT can be difficult, if based solely on the development of thrombocytopenia, because cardiac surgical patients have multiple reasons to be thrombocytopenic. Several clinical scoring systems have been developed to reduce unnecessary testing and better define the pretest probability of HIT, which we will review in detail with a diagnostic algorithm. In addition, we will cover the prevention and treatment HIT.


Subject(s)
Anesthesiologists , Cardiopulmonary Bypass/adverse effects , Critical Care , Heparin/adverse effects , Thrombocytopenia/chemically induced , Anticoagulants/adverse effects , Humans , Postoperative Complications/etiology , Postoperative Complications/prevention & control , Thromboembolism/etiology , Thromboembolism/prevention & control
11.
J Cardiothorac Vasc Anesth ; 32(2): 636-643, 2018 04.
Article in English | MEDLINE | ID: mdl-29129343

ABSTRACT

OBJECTIVES: Blood lactate is frequently used to guide management in critically ill patients. In patients undergoing mitral valve surgery, an elevated lactate level is frequently observed; however, overall mortality is low. The authors hypothesized that hyperlactemia is not a useful predictor of poor outcomes in this patient population. The main aim of this study was to explore how blood lactate level and lactate clearance are associated with 30-day mortality and major adverse events in patients undergoing mitral valve surgery. DESIGN: This was a retrospective database review. Logistic regression analysis was performed to assess the associations of perioperative factors with blood lactate in the intensive care unit (ICU). SETTING: Tertiary-care teaching hospital. PARTICIPANTS: The study comprised 917 patients undergoing mitral valve surgery. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The majority of patients (71.8%) had elevated blood lactate ≥2 mmol/L on ICU admission; however, within 24 hours, 85.1% of all patients had normal lactate values. Overall 30-day mortality was 2.29% (n = 21). The combination of lactate ≥7 mmol/L on ICU admission and a persistent elevated blood lactate level 24 hours after ICU admission provides an excellent prediction of 30-day mortality (C statistic = 0.85). However, even a significantly elevated lactate level on ICU admission was well-tolerated in the majority of patients as long as lactate values normalized within 24 hours. Male sex, longer cardiopulmonary bypass time, blood transfusion in the ICU, and an elevated blood lactate level on ICU admission and 12 hours after ICU admission all were independent risk factors of clearance failure. CONCLUSIONS: An elevated blood lactate level is common after mitral valve surgery and is well-tolerated in the majority of patients. Adding lactate clearance improved the predictive value of the blood lactate level.


Subject(s)
Cardiac Surgical Procedures/trends , Hyperlactatemia/blood , Lactic Acid/blood , Mitral Valve Insufficiency/blood , Mitral Valve Insufficiency/surgery , Aged , Biomarkers/blood , Cardiac Surgical Procedures/mortality , Female , Humans , Hyperlactatemia/diagnosis , Hyperlactatemia/mortality , Length of Stay/trends , Male , Metabolic Clearance Rate/physiology , Middle Aged , Mitral Valve/metabolism , Mitral Valve/surgery , Mitral Valve Insufficiency/mortality , Mortality/trends , Prognosis , Retrospective Studies , Treatment Outcome
14.
16.
Semin Cardiothorac Vasc Anesth ; 21(1): 23-29, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28128019

ABSTRACT

In 2016, demand for the presence of cardiothoracic anesthesiologists outside of the cardiac operating rooms continues to expand. This article is the second in this annual series to review relevant contributions in postoperative cardiac critical care that may impact the cardiac anesthesiologist. We explore the use of extracorporeal membrane oxygenation (ECMO), management of postoperative atrial fibrillation, coagulopathy, respiratory failure, and role of quality in cardiac surgery.


Subject(s)
Atrial Fibrillation/therapy , Cardiac Surgical Procedures , Critical Care/methods , Extracorporeal Membrane Oxygenation/methods , Postoperative Complications/therapy , Respiratory Insufficiency/therapy , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...